Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment

CUB domain‐containing protein 1 (CDCP1) contributes to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance by regulating EGFR signaling pathways and is a potential target in lung cancer treatment. This study aims to identify a CDCP1 reducer that synergistically improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Sze‐Ching, Yeh, Chun‐Chieh, Zhang, Xun‐Yu, Hsieh, Chih‐Ying, Lo, Chia‐Chien, Kuo, Ting‐Ting, Lin, Ching‐Chan, Chao, Chih‐Hua, Liu, Jing‐Pei, Chang, Ling‐Chu, Wang, Lu‐Hai, Sher, Yuh‐Pyng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399713/
https://www.ncbi.nlm.nih.gov/pubmed/37013960
http://dx.doi.org/10.1002/1878-0261.13429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399713/
https://www.ncbi.nlm.nih.gov/pubmed/37013960
http://dx.doi.org/10.1002/1878-0261.13429

Ejemplares similares